HomepageBIOCON • NSE
add
Biocon
Vorige slotkoers
₹ 385,30
Dag-range
₹ 374,85 - ₹ 393,85
Jaar-range
₹ 217,50 - ₹ 394,70
Beurswaarde
450,71 mld. INR
Gem. volume
4,80 mln.
Koers/winst
28,56
Dividendrendement
0,13%
Primaire beurs
NSE
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(INR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 34,33 mld. | 0,30% |
Bedrijfskosten | 20,35 mld. | 9,62% |
Netto inkomsten | 6,60 mld. | 550,59% |
Netto winstmarge | 19,22 | 549,32% |
Winst per aandeel | 5,31 | 524,58% |
EBITDA | 5,96 mld. | -5,39% |
Effectief belastingtarief | 24,77% | — |
Balans
Totale activa
Totale passiva
(INR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 25,74 mld. | -30,92% |
Totale activa | — | — |
Totale passiva | — | — |
Totaal aandelenvermogen | 252,75 mld. | — |
Uitstaande aandelen | 1,20 mld. | — |
Koers-boekwaardeverhouding | 2,33 | — |
Rendement op activa | — | — |
Rendement op kapitaal | 1,29% | — |
Kasstroom
Nettomutatie in liquide middelen
(INR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 6,60 mld. | 550,59% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Opgericht
1978
Hoofdvestiging
Website
Werknemers
16.315